Observational studyThe Journal of infectious diseases2021
Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection.
Observational study in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04360278 (Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19
Who cites it
34 citing papers in PubMed, 62 citations in OpenAlex.
- Perspectives: Educating Transfusion Medicine Professionals in Planetary Health and Infectious Diseases: Should Blood Banks Have Dedicated Infectious Diseases Consultation Services?Open forum infectious diseases · 2025Article
- A multicentre study comparing post-mortem SARS-CoV-2 antibody testing in Cape Town mortuaries.Southern African journal of infectious diseases · 2025Article
- Relationship of various COVID-19 antibody titer with individual characteristics and prediction of future epidemic trend in Xiamen City, China.Journal of thoracic disease · 2024Article
- Article
- Factors Associated with SARS-CoV-2 Infection Evaluated by Antibody Response in a Sample of Workers from the Emilia-Romagna Region, Northern Italy.Antibodies (Basel, Switzerland) · 2023Article
- Assay Harmonization Study To Measure Immune Response to SARS-CoV-2 Infection and Vaccines: a Serology Methods Study.Microbiology spectrum · 2023Article
- Donor selection for adoptive cell therapy with CD45RACytotherapy · 2023Article
- Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States.medRxiv : the preprint server for health sciences · 2023Article
- Immune repertoire sequencing reveals an abnormal adaptive immune system in COVID-19 survivors.Journal of medical virology · 2023Article
- An ecological study on reinfection rates using a large dataset of RT-qPCR tests for SARS-CoV-2 in Santiago of Chile.Frontiers in public health · 2023Article
- Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies.Frontiers in microbiology · 2023Review
- One-Year Follow-Up of COVID-19 Patients Indicates Substantial Assay-Dependent Differences in the Kinetics of SARS-CoV-2 Antibodies.Microbiology spectrum · 2022Article
- Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum.Pathogens (Basel, Switzerland) · 2022Article
- Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants.Cell reports · 2022Article
- SARS-CoV-2-The Role of Natural Immunity: A Narrative Review.Journal of clinical medicine · 2022Review
- Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design.Scientific reports · 2022Article
- COVID-19 vaccination and booster induced authentic-virus neutralizing antibody response is superior to SARS-CoV-2 natural infection induced response.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Article
- Palaeoserology - teeth put into ancient plagues and pandemics.Microbial biotechnology · 2022Article
- Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection.JAMA network open · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundCharacterizing the kinetics of the antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of critical importance to developing strategies that may mitigate the public health burden of coronavirus disease 2019 (COVID-19). We conducted a prospective, longitudinal analysis of COVID-19 convalescent plasma donors at multiple time points over an 11-month period to determine how circulating antibody levels change over time following natural infection.
methodsFrom April 2020 to February 2021, we enrolled 228 donors. At each study visit, subjects either donated plasma or had study samples drawn only. Anti-SARS-CoV-2 donor testing was performed using the VITROS Anti-SARS-CoV-2 Total and IgG assays and an in-house fluorescence reduction neutralization assay.
resultsAnti-SARS-CoV-2 antibodies were identified in 97% of COVID-19 convalescent donors at initial presentation. In follow-up analyses, of 116 donors presenting at repeat time points, 91.4% had detectable IgG levels up to 11 months after symptom recovery, while 63% had detectable neutralizing titers; however, 25% of donors had neutralizing levels that dropped to an undetectable titer over time.
conclusionsOur data suggest that immunological memory is acquired in most individuals infected with SARS-CoV-2 and is sustained in a majority of patients for up to 11 months after recovery. Clinical Trials Registration. NCT04360278.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.